“small” T3 short-term RT and TME “large” T3 long-term CRT and TME T4 long term CRT and TME Therefore: tailored treatment.

Slides:



Advertisements
Similar presentations
Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden
Advertisements

What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated surgically resectable liver Metastases? – Systemic.
Neoadjuvant therapy for Rectal cancer
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Results of the Prodige 2-ACCORD 12/0405 Randomized trial comparing two neoadjuvant chemo-radiotherapy (Cape 45 vs Capox 50) in patients with T3-4 rectal.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.
Statements on Head and Neck Cancer 2006 Primary Radiochemotherapy Arlene A. Forastiere, M.D. Johns Hopkins University School of Medicine Department of.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.
What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? - Chemoradiation followed by surgery Bruce Minsky.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
MRC CR07: 5x5 TME vs. TME RCT in 3y Preop. RT + OP (n=674)
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Colorectal Cancer An oncologists perspective
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Hot topics in breast radiotherapy Mark Beresford.
Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.
AATS/STS General Thoracic Surgery Symposium
Chemoradiotherapy for Rectal cancer Dr. A. Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
RECTAL CANCER The (neo)adjuvant story
What to do in stage III non small-cell lung cancer? Miklos Pless 28. November 2013.
What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.
The Treatment of the Axilla in the North of England Cancer Network. Henry Cain ST7 North Tyneside.
CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.
TME trial TME radiotherapy 5 x 5 Gy TME alone randomisation n = 1861 resectable rectal carcinoma if CRM+: 50 GY.
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.
Rectal Cancer: French Prodige Study: Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.
RT with TME surgery ? OUTLINEOUTLINE. Prostate Seminal vessels Neurovascular bundle Denonvilliers Fascia “holy plane” (Fascia rectalis) Total Mesorectal.
Exit Examinations European view M62 Coloproctolgy course, Huddersfield Lars Påhlman Dept. Surgery, Colorectal unit University Hospital, Uppsala, Sweden.
Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR.
CJ Allegra, G Yothers, MJ O’Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark Neoadjuvant Therapy For Rectal Cancer: Mature Results.
AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012.
Local recurrence after rectal cancer resection is strongly related to the plane of surgical (PoS) dissection and is further reduced by pre-operative short.
Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial Authors: Oliver et al,
NPC Treatment Outcomes: Disease Control and Failure Patterns Sandeep Samant, MS, FRCS.
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.
Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.
Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Multidisciplinary treatment of rectal cancer. Medical oncology Carlo Aschele E.O. Ospedali Galliera – Genova - Italy Carlo Aschele E.O. Ospedali Galliera.
Rectal Cancer MOTP Half Day September 9, 2008
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Gastrointestinal Cancer
Which preoperative regimen in rectal cancer?
Is there a role for adjuvant oxaliplatin in rectal cancer? - YES! -
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
Neoadjuvant therapy of rectal cancer – how can we make it better?
What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases?
Systemic chemotherapy->chemoradiation->surgery.
Volume 373, Issue 9666, Pages (March 2009)
Christopher Crane, MD Professor, Dept of Radiation Oncology
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Locally Advanced NSCLC Implementing Innovation
Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer
Do we need post-operative CHEMOTHERAPY in patients with PATHOLOGIC Complete Response to neoadjuvant therapy in RECTAL CANCER ? Philippe Rougier ESDO Board(European.
Alan P. Venook, MD University of California, SF
What’s new in stage III lung cancer?
Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes - 
 Bruce Minsky.
Fig. 2. Change in mean International Index of Erectile Function (IIEF-5) scores from preoperative (preop) visit to postoperative 2-year visit for all patients.
Presentation transcript:

“small” T3 short-term RT and TME “large” T3 long-term CRT and TME T4 long term CRT and TME Therefore: tailored treatment

Stage III p < % 20.6%20.6% TME RT+TME

Stage III and CRM negative p < % 19.7%19.7% TME RT+TME

T1: TME alone T2 /T3: preoperative RT (5x5 Gy) +TME T3 threatened CRM: preoperative CRT+TME T4: preoperative CRT+TME Tailored treatment with MRI scanning

p = % TME 65% RT+TME Peeters, in press Overall Survival Dutch trial

pre-op (n=674) postop (n=676) p 5 yr LR4.7%11.q%< yr DFS79.5%74.9% yr OS80.8%78.7%0.07 Sebag Montefiore, ASCO 2006 MRC CR07 survival

Overall survival Survival in 40 years: 60%

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.